he’s also fighting to ... lower the cost of prescription drugs like insulin
Warnock will fight to lower prescription drug costs for families, including insulin costs.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
Reverend Warnock is fighting to lower the cost of prescription drugs for hardworking families, including lowering the cost of prescription drugs like insulin.
legacy_unverified · Source version not recorded · locator unknown
Sponsor: Sen. Warnock, Raphael G. [D-GA] (Introduced 02/11/2025). The bill is titled the Capping Prescription Costs Act of 2025 and seeks to limit cost-sharing for prescription drugs.
legacy_unverified · Source version not recorded · locator unknown
The legislation would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals and $4,000 for families with private insurance.
legacy_unverified · Source version not recorded · locator unknown
Section 11406 creates appropriate cost-sharing for covered insulin products under Medicare Part D, including no deductible and cost-sharing not to exceed the applicable copayment amount for a month’s supply.
legacy_unverified · Source version not recorded · locator unknown
Vote Result: Passed. Question: On Passage of the Bill: H.R. 5376, As Amended. This was the Senate’s final passage vote on the Inflation Reduction Act package that carried the insulin and prescription-drug provisions.
legacy_unverified · Source version not recorded · locator unknown
The law provides a yearly cap ($2,000 in 2025) on out-of-pocket prescription drug costs in Medicare and says people with Medicare who take insulin covered by their prescription drug plan will have access to each insulin for no more than $35 for a month’s supply.
legacy_unverified · Source version not recorded · locator unknown
The HELP Committee legislation page lists “INSULIN Act of 2026,” bill S.4189, with Last Action 08/07/2026.
legacy_unverified · Source version not recorded · locator unknown
CMS says 2026 Part D IRA benefits continue, including the insulin cost-sharing cap and catastrophic coverage after a $2,100 threshold.
Assessments
Warnock materially acted on the promise during his Senate term: he voted for the Inflation Reduction Act, which enacted Medicare prescription-drug reforms including a $35 monthly insulin cost-sharing cap and Medicare out-of-pocket drug limits, and he later introduced broader bills to cap prescription costs and insulin costs. However, the enacted delivery is narrower than the promise's broad framing for families generally, because the main completed insulin and prescription-drug caps apply chiefly to Medicare beneficiaries rather than all families or the private market. Broader family/private-market caps remain legislative efforts rather than enacted outcomes.
Warnock promised to fight to lower prescription drug costs, including insulin. During his Senate term, the Inflation Reduction Act passed with his chamber support and enacted major prescription-drug reforms, including a $35 monthly insulin cap for Medicare beneficiaries and a $2,000 annual Medicare out-of-pocket prescription-drug cap beginning in 2025. The delivery was not universal for all families or all private insurance insulin users, but the pledge was framed as fighting to lower costs rather than guaranteeing a comprehensive universal cap, and a substantial federal prescription-drug and insulin-cost reduction became law in the same term. His later sponsorship of broader prescription-cost cap legislation reinforces continued effort but is not needed for the core delivery finding.